Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 4:05 AM
Ignite Modification Date: 2025-12-25 @ 4:05 AM
NCT ID: NCT04288102
Eligibility Criteria: Inclusion Criteria: 1. Male or female, aged at 18 years (including) -75 years old 2. Hospitalized 3. Laboratory confirmation of SARS-CoV-2 infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source 4. Pneumonia that is judged by computed tomography 5. In accordance with any one of the following : 1)dyspnea (RR ≥ 30 times / min), 2)finger oxygen saturation ≤ 93% in resting state, 3)arterial oxygen partial pressure (PaO2) / oxygen absorption concentration (FiO2) ≤ 300MMHG, 4)pulmonary imaging shows that the focus progress \> 50% in 24-48 hours 6. Interstitial lung damage is judged by computed tomography. Exclusion Criteria: 1. Pregnancy, lactation and those who are not pregnant but do not take effective contraceptives measures; 2. Patients with malignant tumor, other serious systemic diseases and psychosis; 3. Patients who are participating in other clinical trials; 4. Inability to provide informed consent or to comply with test requirements. 5. Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus. 6. Invasive ventilation 7. Shock 8. Combined with other organ failure( need organ support) 9. Interstitial lung damage caused by other reasons ( in 2 weeks) 10. The pulmonary imaging revealed the interstitial damage of lungs before the COVID-19 confirmed.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT04288102
Study Brief:
Protocol Section: NCT04288102